| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BRIEF REVIEWS |
* Division of Nephrology and Hypertension and
Division of Rheumatology, Departments of Medicine and Immunology, University of Colorado Health Sciences Center, Denver, CO 80262
The complement system is increasingly recognized as important in the pathogenesis of tissue injury in vivo following immune, ischemic, or infectious insults. Within the complement system, three pathways are capable of initiating the processes that result in C3 activation: classical, alternative, and lectin. Although the roles that proinflammatory peptides and complexes generated during complement activation play in mediating disease processes have been studied extensively, the relative contributions of the three activating pathways is less well understood. Herein we examine recent evidence that the alternative complement pathway plays a key and, in most instances, obligate role in generating proinflammatory complement activation products in vivo. In addition, we discuss new concepts regarding the mechanisms by which the alternative pathway is activated in vivo, as recent clinical findings and experimental results have provided evidence that continuous active control of this pathway is necessary to prevent unintended targeting and injury to self tissues.
This article has been cited by other articles:
|
|
 |
|
  P. Lundh von Leithner, J. H. Kam, J. Bainbridge, I. Catchpole, G. Gough, P. Coffey, and G. Jeffery Complement Factor H Is Critical in the Maintenance of Retinal Perfusion Am. J. Pathol., July 1, 2009; 175(1): 412 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Thurman, B. Renner, K. Kunchithapautham, V. P. Ferreira, M. K. Pangburn, Z. Ablonczy, S. Tomlinson, V. M. Holers, and B. Rohrer Oxidative Stress Renders Retinal Pigment Epithelial Cells Susceptible to Complement-mediated Injury J. Biol. Chem., June 19, 2009; 284(25): 16939 - 16947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Katschke Jr., S. Stawicki, J. Yin, M. Steffek, H. Xi, L. Sturgeon, P. E. Hass, K. M. Loyet, L. DeForge, Y. Wu, et al. Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement J. Biol. Chem., April 17, 2009; 284(16): 10473 - 10479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Savage, R. K. Semple, M. R. Clatworthy, P. A. Lyons, B. P. Morgan, E. K. Cochran, P. Gorden, P. Raymond-Barker, P. R. Murgatroyd, C. Adams, et al. Complement Abnormalities in Acquired Lipodystrophy Revisited J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 10 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang, F. Qiao, C. Atkinson, V. M. Holers, and S. Tomlinson A Novel Targeted Inhibitor of the Alternative Pathway of Complement and Its Therapeutic Application in Ischemia/Reperfusion Injury J. Immunol., December 1, 2008; 181(11): 8068 - 8076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hakobyan, C. L. Harris, C. W. van den Berg, M. C. Fernandez-Alonso, E. G. de Jorge, S. R. de Cordoba, G. Rivas, P. Mangione, M. B. Pepys, and B. P. Morgan Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein J. Biol. Chem., November 7, 2008; 283(45): 30451 - 30460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ramo, S. M. Cashman, and R. Kumar-Singh Evaluation of Adenovirus-Delivered Human CD59 as a Potential Therapy for AMD in a Model of Human Membrane Attack Complex Formation on Murine RPE Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4126 - 4136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhou, W. Hu, and X. Qin The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy Oncologist, September 1, 2008; 13(9): 954 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, D. Spitzer, D. Mao, S. L. Peng, H. Molina, and J. P. Atkinson Membrane Protein Crry Maintains Homeostasis of the Complement System J. Immunol., August 15, 2008; 181(4): 2732 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, J.-Y. Zhu, and Z.-X. Niu Molecular Structure and Expression of Anthropic, Ovine, and Murine Forms of Complement Receptor Type 2 Clin. Vaccine Immunol., June 1, 2008; 15(6): 901 - 910. [Full Text] [PDF]
|
|
|
|
 |
|
 G. I. Gomes, E. P. Nahn Jr., R. K. R. G. Santos, W. D. Da Silva, and T. L. Kipnis The Functional State of the Complement System in Leprosy Am J Trop Med Hyg, April 1, 2008; 78(4): 605 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Paglialunga, A. Fisette, Y. Yan, Y. Deshaies, J.-F. Brouillette, M. Pekna, and K. Cianflone Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E521 - E529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Le, G. Abbenante, and D. P. Fairlie Profiling the Enzymatic Properties and Inhibition of Human Complement Factor B J. Biol. Chem., November 30, 2007; 282(48): 34809 - 34816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Verdeguer, C. Castro, M. Kubicek, D. Pla, M. Vila-Caballer, A. Vinue, F. Civeira, M. Pocovi, J. J. Calvete, and V. Andres Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation Cardiovasc Res, November 1, 2007; 76(2): 340 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Banda, K. Takahashi, A. K. Wood, V. M. Holers, and W. P. Arend Pathogenic Complement Activation in Collagen Antibody- Induced Arthritis in Mice Requires Amplification by the Alternative Pathway J. Immunol., September 15, 2007; 179(6): 4101 - 4109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Markiewski and J. D. Lambris The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight Am. J. Pathol., September 1, 2007; 171(3): 715 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Spitzer, L. M. Mitchell, J. P. Atkinson, and D. E. Hourcade Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly J. Immunol., August 15, 2007; 179(4): 2600 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lenderink, K. Liegel, D. Ljubanovic, K. E. Coleman, G. S. Gilkeson, V. M. Holers, and J. M. Thurman The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy Am J Physiol Renal Physiol, August 1, 2007; 293(2): F555 - F564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Katschke Jr., K. Y. Helmy, M. Steffek, H. Xi, J. Yin, W. P. Lee, P. Gribling, K. H. Barck, R. A.D. Carano, R. E. Taylor, et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis J. Exp. Med., June 11, 2007; 204(6): 1319 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mihai, M. T. Chiriac, K. Takahashi, J. M. Thurman, V. M. Holers, D. Zillikens, M. Botto, and C. Sitaru The Alternative Pathway of Complement Activation Is Critical for Blister Induction in Experimental Epidermolysis Bullosa Acquisita J. Immunol., May 15, 2007; 178(10): 6514 - 6521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wehner, C. N. Morrell, T. Reynolds, E. R. Rodriguez, and W. M. Baldwin III Antibody and Complement in Transplant Vasculopathy Circ. Res., February 2, 2007; 100(2): 191 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Thurman, A. M. Lenderink, P. A. Royer, K. E. Coleman, J. Zhou, J. D. Lambris, R. A. Nemenoff, R. J. Quigg, and V. M. Holers C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion J. Immunol., February 1, 2007; 178(3): 1819 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Rupprecht, B. Angele, M. Klein, J. Heesemann, H.-W. Pfister, M. Botto, and U. Koedel Complement C1q and C3 Are Critical for the Innate Immune Response to Streptococcus pneumoniae in the Central Nervous System J. Immunol., February 1, 2007; 178(3): 1861 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Papp, Z. Szekeres, N. Terenyi, A. Isaak, A. Erdei, and J. Prechl On-chip Complement Activation Adds an Extra Dimension to Antigen Microarrays Mol. Cell. Proteomics, January 1, 2007; 6(1): 133 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Xiao, A. Schreiber, P. Heeringa, R. J. Falk, and J. C. Jennette Alternative Complement Pathway in the Pathogenesis of Disease Mediated by Anti-Neutrophil Cytoplasmic Autoantibodies Am. J. Pathol., January 1, 2007; 170(1): 52 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Spitzer, X. Wu, X. Ma, L. Xu, K. P. Ponder, and J. P. Atkinson Cutting Edge: Treatment of Complement Regulatory Protein Deficiency by Retroviral In Vivo Gene Therapy J. Immunol., October 15, 2006; 177(8): 4953 - 4956. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
